Phase 2b trial

Related by string. Phase 2b Trial * phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical . pivotal Phase III / 2Bs . 2BD . 2B : 2B Marcus Giles . Phase 2b clinical . 2B Luis Castillo . 2B Freddy Sanchez / trialed . trialing . trials . Trial : Week Premium Trial . randomized controlled trial . randomized controlled trials . placebo controlled clinical trials * *

Related by context. All words. (Click for frequent words.) 82 Phase 2a trial 81 Phase 2b study 81 Phase IIb trial 80 Phase Ib 79 Phase IIa trial 78 Phase IIb 78 Phase 2a clinical 78 Phase 2b clinical 78 Phase 2a 78 Phase 1b 77 Phase IIb clinical 77 Phase III 77 phase IIa clinical 77 pivotal Phase III 76 dose escalation trial 76 Phase Ib clinical 76 Phase 1b trial 76 Phase 2b 76 Phase IIa clinical 76 Phase IIa 75 phase IIb 75 Phase III clinical 75 Phase Ib study 75 Phase IIIb clinical 74 phase IIa 74 phase IIb clinical 74 confirmatory Phase III 74 Phase 1b clinical 74 Phase IIb trials 74 phase IIb trial 73 Phase III trials 73 phase Ib 73 clinical trial 72 IIa trial 72 Phase Ib II 72 pivotal Phase 72 placebo controlled Phase 72 dose escalation study 72 dose escalation Phase 72 Phase III clinical trials 71 Phase III pivotal 71 Phase II 71 Phase 1a 71 multicenter Phase 70 Phase Ia 70 phase IIb study 70 dose cohorts 70 registrational 69 randomized Phase 69 Phase IIa trials 69 placebo controlled clinical 69 registrational trial 69 Phase #b/#a 69 multicenter Phase II 69 GALNS 69 INCB# [001] 69 placebo controlled Phase III 69 Phase IIB 69 multiple ascending dose 69 Phase 1a clinical 69 Phase IIIb 68 axitinib 68 PEG PAL 68 elotuzumab 68 dose escalation 68 ADVANCE PD 68 dirucotide 68 Alzhemed TM 68 BRIM2 68 alvespimycin 68 Phase Ib clinical trials 67 JAK inhibitor 67 phase 2a 67 Plicera 67 SUCCEED trial 67 lintuzumab 67 dose escalation clinical 67 Phenoptin 67 placebo controlled 67 Amrubicin 67 dose cohort 67 Phase 2b randomized 67 RG# [001] 67 Phase IIb clinical trials 67 multicenter clinical 67 mipomersen 67 IIa clinical trial 67 Phase 2b clinical trials 67 brivaracetam 67 ofatumumab 66 forodesine 66 confirmatory Phase 3 66 PRX # 66 huC# DM4 66 clinical trials 66 double blinded placebo 66 HuMax CD# 66 BRIM3 66 CR# vcMMAE 66 bicifadine 66 single ascending dose 66 pivotal bioequivalence 66 double blind placebo 66 Phase III randomized controlled 66 clinical pharmacology studies 66 HuMax CD4 66 randomized controlled Phase 66 pharmacokinetic PK 66 budesonide foam 66 oral ridaforolimus 66 Phase #b/#a trial 66 INCB# [002] 66 BAY #-# 66 AQ4N 66 pharmacokinetic PK study 66 Amigal 65 phase Ib clinical 65 IMGN# 65 teduglutide 65 TMC# C# 65 APEX PD 65 HGS ETR1 65 randomized Phase 2b 65 OvaRex ® MAb 65 Dacogen injection 65 ganetespib 65 randomized Phase III 65 cannabinor 65 cetrorelix 65 randomized Phase IIb 65 IND submission 65 oral deforolimus 65 multicenter phase 65 EOquin 65 Aryplase 65 multicentre randomized 65 Cloretazine R VNP#M 65 valopicitabine 65 Traficet EN 65 Zenvia Phase III 65 HGS# 65 Phase III placebo controlled 65 Phase IIa clinical trials 65 RSD# oral 65 multicenter 65 blinatumomab 65 midstage trials 65 randomized placebo controlled 65 investigational compound 65 CEQ# 64 initiate Phase IIb 64 pertuzumab 64 Phase IIIb study 64 BLA filing 64 Asentar 64 TACI Ig 64 tanespimycin 64 HspE7 64 PXD# 64 ruxolitinib 64 teriflunomide 64 ADAGIO study 64 ATL# [001] 64 Phase III randomized 64 Zenvia ™ 64 rALLy clinical trial 64 MGCD# [001] 64 enzastaurin 64 SYMMETRY trial 64 obatoclax 64 Urocidin 64 HCV SPRINT 64 Phase #/#a trial 64 BLA submission 64 PSMA ADC 64 MEND CABG 64 celgosivir 64 relapsed refractory multiple myeloma 64 TG MV 64 IMA# 64 II Clinical Trial 64 AEG# 64 metastatic hormone refractory 64 Phase III psoriasis 64 Phase 2a clinical trials 64 COMFORT II 64 alvimopan 64 omacetaxine mepesuccinate 64 ongoing Phase 1b 64 vidofludimus 64 ELACYT 64 Fibrillex TM 64 ITAX 64 rALLy trial 64 TELINTRA 64 Phase 2b kidney transplant 64 MEK inhibitor 64 Fx #A 64 CCX# 64 EOquin TM 64 sapacitabine 64 methylnaltrexone 64 KRN# 64 CA4P 64 opioid induced bowel dysfunction 64 lomitapide 64 ISIS # 64 neratinib 64 AP# [003] 64 initiate Phase 2b 63 IMC A# 63 Phase 63 randomized multicenter 63 blinded randomized placebo controlled 63 European Sepsis Trial 63 BCX# 63 PSN# [002] 63 HCD# [002] 63 glufosfamide 63 FOLOTYN 63 APTIVUS 63 Phase #b/#a clinical 63 multicenter randomized placebo controlled 63 mertansine 63 tolerability 63 CRx 63 NO# [002] 63 R#/MEM # 63 PDE4 inhibitor 63 MERLIN TIMI 63 pomalidomide 63 PRECiSE 63 MAA submission 63 Mipomersen 63 initiate Phase Ib 63 deforolimus 63 cell lymphoma CTCL 63 Phase 1b dose escalation 63 tivozanib 63 phase IIIb 63 PRECISE trial 63 fosbretabulin 63 ozarelix 63 ILLUMINATE 63 dose dose escalation 63 EDEMA3 63 nonclinical studies 63 elacytarabine 63 Triolex 63 sunitinib malate 63 zanolimumab 63 refractory CLL 63 GLP toxicology studies 63 LUX Lung 63 blind randomized placebo 63 PF # [001] 63 nab paclitaxel 63 relapsing remitting multiple sclerosis 63 Marqibo 63 HuMax EGFr 63 otelixizumab 63 lintuzumab SGN 63 Phase #/#a 63 multicenter randomized Phase 63 Proxinium TM 63 dosing cohort 63 eniluracil 63 Shigamabs ® 63 huN# DM1 63 YONDELIS 63 Cloretazine ® 63 placebo controlled randomized 63 ZYBRESTAT 63 Zerenex 63 tremelimumab 63 rindopepimut 63 NGX# 62 CLARITY study 62 OPT CHF 62 TELCYTA 62 rNAPc2 62 EndoTAG TM -1 62 tramiprosate Alzhemed TM 62 evaluating tivozanib 62 PS# [001] 62 PEG SN# 62 XmAb# 62 pradefovir 62 Viramidine 62 MOZOBIL 62 midstage studies 62 Androxal TM 62 pharmacokinetic studies 62 OvaRex R 62 viral kinetic 62 DDP# 62 daclizumab 62 ENDEAVOR IV 62 unblinding 62 Phase III Pivotal 62 FOLOTYN ® 62 CB2 selective receptor agonist 62 ularitide 62 TOLAMBA 62 label dose escalation 62 Phase III confirmatory 62 torezolid phosphate 62 CoFactor 62 GAMMAGARD 62 TASKi2 62 Phase 1b clinical trials 62 T DM1 62 diabetic neuropathic pain 62 randomized double 62 IDX# 62 Clavis Pharma 62 ANCHOR trial 62 HoFH 62 TMC# [002] 62 Augment Injectable 62 treatment naive genotype 62 PRE SURGE 62 multicenter randomized double 62 SinuNase 62 investigational humanized monoclonal antibody 62 dirucotide MBP# 62 Randomized Phase 62 PRTX 62 lorvotuzumab mertansine 62 ARDIS 62 dosing cohorts 62 Rezular 62 octreotide implant 62 PROMACTA 62 IL# PE#QQR 62 dacetuzumab 62 NOX E# 62 tesmilifene 62 Annamycin 62 AEGR 62 RSD# 62 SNT MC# 62 RDEA# 62 Phase III Clinical Trial 62 metastatic HRPC 62 LymphoStat B 62 multicenter Phase III 62 PFO migraine 62 AZILECT R 62 Degarelix 62 dexpramipexole 62 docetaxel Taxotere R 62 voreloxin 62 randomized multicenter Phase III 62 Bicifadine 62 MEND CABG II 62 HuLuc# 62 Ophena TM 62 Azedra 62 Allovectin 7 R 62 IMPACT IMmunotherapy 62 oral formulation 62 amrubicin 62 investigational drug 62 phase IIb III 62 PA# [002] 62 oral prodrug 62 investigational pan BCR 62 HGS ETR2 62 IMC #B 62 perifosine 62 Corlux 62 NDA submission 62 Archexin 62 Diamyd ® 62 IIa clinical 61 DR Cysteamine 61 XL# [003] 61 Laquinimod 61 Sym# 61 carfilzomib 61 Allovectin 7 61 relapsing multiple sclerosis 61 lumiliximab 61 Cethrin 61 ALN TTR# 61 ZYBRESTAT fosbretabulin 61 ocrelizumab 61 AVADO 61 NP2 Enkephalin 61 NUVIGIL 61 CHAMPION PCI 61 PEG Interferon lambda 61 Enobia 61 Icatibant 61 anticancer compound 61 Zenvia 61 vilazodone 61 atacicept 61 double blinded randomized 61 HER2 positive metastatic breast 61 pharmacokinetics PK 61 mapatumumab 61 LibiGel Phase III 61 ataluren 61 AIR CF1 61 maribavir 61 PD LID 61 PREOS R 61 PANVAC VF 61 PRT# 61 ASA# 61 Maximum Tolerated Dose 61 HQK 61 assessing T DM1 61 MAXY alpha 61 Alocrest 61 Azedra TM 61 apremilast 61 ABSORB trial 61 pharmacokinetic 61 subcutaneous formulation 61 denufosol 61 elagolix 61 Myocet 61 OncoVEX GM CSF 61 pralatrexate 61 Pivotal Trial 61 Ceflatonin 61 COSIRA trial 61 linaclotide 61 Cimzia ® certolizumab pegol 61 MBP# [001] 61 fostamatinib 61 Memryte 61 adecatumumab 61 belinostat 61 KNS # 61 SAR# [004] 61 CLIRS trial 61 IIb clinical trial 61 Onalta ™ 61 riociguat 61 initiate Phase 61 CIMZIA TM 61 ALN VSP Phase 61 PLK1 SNALP 61 Santhera 61 eltrombopag 61 PREOS 61 rilonacept 61 tezampanel 61 picoplatin 61 REG2 61 ascending dose 61 entinostat 61 Dextofisopam 61 TG# [003] 61 histone deacetylase HDAC inhibitor 61 Troxatyl 61 PROPEL trial 61 Evoltra TM 61 ELND# 61 prospective multicenter 61 Initiate Phase 61 randomized controlled 61 AZILECT ® 61 JZP 61 FORTIS M trial 61 hormone refractory prostate cancer 61 Pivotal Phase 61 AeroLEF TM 61 oral methylnaltrexone 61 rALLy 61 Phase III VISTA 61 GED aPC 61 dexanabinol 61 TORISEL 61 EVIZON 61 varespladib 61 severe hypercholesterolemia 61 Pivotal Phase III 61 JAK1 61 pharmacodynamic PD 61 Aurora kinase inhibitor 61 urocortin 2 61 GetGoal Phase III 61 AZD# 61 MAP# 61 bendamustine 61 Phase IIb kidney transplant 61 davunetide intranasal AL 61 OXi# 61 Aflibercept 61 EFAPROXYN 61 Virulizin ® 61 Phase III Clinical Trials 61 XL# SAR# 61 MAGE A3 ASCI 60 HCV RESPOND 2 60 MGd 60 Phase 2b Clinical Trial 60 Tarceva TM 60 Personalized Immunotherapy 60 Feasibility Trial 60 active comparator 60 Phase III ALLEGRO 60 metaglidasen 60 relapsed multiple myeloma 60 RhuDex ® 60 IND enabling 60 Tyrima 60 HCV protease inhibitor 60 Pivotal Study 60 Exherin TM 60 albinterferon alfa 2b 60 recurrent glioma 60 multicenter placebo controlled 60 APEX AMI trial 60 Phase IIb III 60 eculizumab 60 Elocalcitol 60 adecatumumab MT# 60 multicenter prospective 60 REVLIMID lenalidomide 60 clofarabine 60 alogliptin 60 Investigational Device Exemption IDE 60 aflibercept 60 refractory multiple myeloma 60 dextromethorphan quinidine 60 masked placebo controlled 60 receptor tyrosine kinase inhibitor 60 prospective multicenter randomized 60 Genz # 60 TBC# 60 MT#/MEDI-# 60 nitazoxanide 60 PROSTVAC ® 60 unblind 60 RGB # 60 trastuzumab DM1 T DM1 60 ProSavin 60 Prostate AdenoCarcinoma Treatment 60 dose escalation phase 60 perifosine KRX 60 Chemophase 60 Tavocept 60 incyclinide 60 ascending doses 60 Nuvion 60 tolerated dose MTD 60 Omacetaxine 60 Ocrelizumab 60 Bezielle 60 IRX 2 60 GRN#L 60 generation purine nucleoside 60 vicriviroc 60 desvenlafaxine succinate 60 BiTE antibody 60 SEPET TM 60 sNDA submission 60 LCP AtorFen 60 virus HCV protease inhibitor 60 MIST II 60 mg/m2 cohort 60 SUTENT 60 Phase Ib IIa 60 figitumumab 60 Safinamide 60 SCH # 60 TG# [001] 60 ToGA 60 NVA# 60 trastuzumab emtansine T DM1 60 blinded placebo controlled 60 multicenter randomized 60 Nexavar sorafenib 60 DermaVir Patch 60 docetaxel chemotherapy 60 PRIMO CABG 60 alemtuzumab Campath 60 darusentan 60 OHR/AVR# 60 EDEMA4 60 Prodarsan 60 Vilazodone 60 Zenvia TM 60 PreCISe study 60 multicentre 60 AIR CF2 60 ThermoDox R 60 atrasentan 60 CCR5 mAb 60 lupus nephritis 60 DEB# 60 pitavastatin 60 Ozarelix 60 Targretin 60 initiate Phase 1b 60 EchoCRT 60 lubiprostone 60 Altastaph 60 talactoferrin 60 Trofex 60 PHX# 60 ENRICH trial 60 MNTX 60 stated Michelle Berrey 60 ATryn R 60 metastatic castration resistant 60 APPRAISE 60 preclinical 60 nalbuphine ER 60 Restanza 60 refractory metastatic colorectal cancer 60 eprotirome 60 Ceflatonin R 60 Virulizin R 60 Genasense ® 60 Phase lll 60 CytoFabTM 60 Phase III TRIST 60 Phase III Psoriasis 60 NCCTG 60 TLK# 60 olaparib 60 Pimavanserin 60 Spiegelmer ® 60 treatment naïve genotype 60 PNP inhibitor 60 Phase IIb Clinical Trial 60 PRECISE Trial 60 multicenter randomized controlled 60 Phase 2b monotherapy 60 CRLX# 60 Hedgehog antagonist 60 MEK inhibitor RDEA# 60 Fodosine 60 randomized clinical 60 Firazyr 60 Synavive 60 ONTAK 59 Neurodex 59 non nucleoside inhibitor 59 Microplasmin 59 subcutaneously administered 59 refractory APL 59 VNP#M 59 Zybrestat 59 initiated Phase Ib 59 Aurexis 59 Plenaxis TM 59 velafermin belinostat 59 preclinical efficacy 59 Locteron 59 SPIRIT FIRST 59 neurogenic orthostatic hypotension 59 Xanafide 59 CD# antibody [001] 59 LEP ETU 59 Phase IIb Trial 59 crofelemer 59 lorcaserin Phase 59 prospective randomized placebo 59 ANTEGREN 59 INT# [002] 59 multicenter study 59 Factor VIIa 59 Sapacitabine 59 RHUCIN 59 Carfilzomib 59 Golimumab 59 preclinical studies 59 Serdaxin 59 pharmacodynamic profile 59 GRNVAC1 59 Ixempra 59 protein kinase inhibitor 59 LEVADEX 59 tgAAC# 59 ENMD # 59 ganaxolone 59 Marketing Authorization Application 59 Velcade bortezomib 59 ponatinib 59 QLT# 59 novel histone deacetylase 59 rFIXFc 59 recurrent malignant glioma 59 CCR5 antagonist 59 Tamibarotene 59 bardoxolone 59 personalized immunotherapy 59 Apoptone 59 Valortim 59 baminercept 59 cilengitide 59 Omigard 59 ThermoDox ® 59 mRCC 59 registrational studies 59 iclaprim 59 vascular disrupting agent 59 Aplidin 59 Quinamed 59 panitumumab 59 microplasmin 59 Urocortin 2 59 monotherapy 59 RezularTM 59 Darusentan 59 PDX pralatrexate 59 Panzem R NCD 59 BNC# 59 CLL8 59 crizotinib PF # 59 ThGRF 59 lesinurad 59 vosaroxin 59 dyskinesia PD LID 59 tramiprosate ALZHEMED TM 59 omega interferon 59 IMPACT DCM 59 Dr. Fahar Merchant 59 LymphoStat B TM 59 sunitinib 59 REMUNE R 59 Atiprimod 59 velafermin 59 AIR CF3 59 Allovectin 7 ® 59 Itopride 59 label multicenter 59 Locteron ® 59 PROSTVAC TM 59 SUTENT ® 59 VEGF Trap 59 pharmacodynamic effects 59 TRANSFORMS 59 Q#IR 59 ACAPODENE 59 LY# [003] 59 tolevamer 59 Treanda 59 metastatic sarcomas 59 fidaxomicin Phase 3 59 goserelin 59 recurrent GBM 59 Torisel 59 palifosfamide 59 orBec 59 CALGB 59 L BLP# 59 viral kinetics 59 Phase IIA 59 Acapodene 59 nucleotide analog 59 prospective randomized 59 Rebif ® 59 Aplidin R 59 maximally tolerated dose 59 isavuconazole 59 REVIVE Diabetes 59 TOCOSOL Paclitaxel 59 IIa trials 59 Cloretazine 59 efficacy endpoint 59 Initiated Phase 59 PROVENGE sipuleucel T 59 pegloticase 59 ALN TTR 59 JAK2 inhibitor 59 selective androgen receptor modulator 59 Clinical Oncology Annual Meeting 59 decitabine 59 depsipeptide 59 ospemifene 59 GOUT 59 peginesatide 59 EMPHASIS HF trial 59 Dyloject TM 59 confirmatory clinical 59 Viprinex TM 59 Elagolix 59 Dose escalation 59 Enzastaurin 59 ANAVEX #-# [003] 59 Loramyc R 59 arzoxifene 59 preclinically 59 Insegia 59 AZX# 59 ZACTIMA 59 FAME Study 59 StaphVAX 59 tafamidis 59 romidepsin 59 Azilect ® 59 metastatic renal cell carcinoma 59 danoprevir 59 STRIDE PD 59 label multicenter randomized 59 diarrhea predominant irritable 59 cutaneous T cell 59 interferon beta 1b 59 prucalopride 59 INCB# [003] 59 phase III ACCLAIM 59 ofatumumab HuMax CD# 59 refractory cutaneous T 59 CIMZIA ™ 59 Cotara 59 placebo controlled clinical trials 59 temozolomide 59 CRMD# 59 visilizumab 59 leukemia AML 59 controlled multicenter 59 Dapagliflozin 59 Azixa 59 AIMM trial 59 satraplatin 59 evaluating RDEA# 59 CTCE 59 prospectively defined 59 budesonide MMX 59 generation PNP inhibitor 59 satraplatin Phase 59 CUSTOM III 59 resminostat 59 telaprevir dosing 59 AMEVIVE 59 ORENCIA R 59 humanized anti 59 Cimzia TM 58 MLN# 58 Matrix Phase 2b 58 MONOVISC 58 Blinatumomab 58 tolerability profile 58 AACR NCI EORTC 58 orally bioavailable 58 CDP# 58 mixed dyslipidemia 58 ASONEP 58 ixabepilone 58 multicentre randomized double 58 PEGPH# 58 prospective observational 58 pafuramidine 58 Phase #/#a clinical 58 castrate resistant prostate cancer 58 TEMSO 58 icatibant 58 GLPG# 58 trodusquemine 58 initiate Phase IIa 58 Evamist TM 58 TASQ 58 midstage clinical 58 Stedivaze 58 metastatic renal cell 58 glucokinase activator 58 ENESTnd 58 CCX# B 58 castration resistant prostate cancer 58 EndoTAG 58 Desmoteplase 58 Iluvien 58 PRX# 58 MORAb 58 dalbavancin 58 LUMINATE 58 dosing regimens 58 regorafenib 58 abiraterone acetate 58 radiation sensitizer 58 pharmacokinetic profile 58 acyclovir Lauriad R 58 unblinded 58 CYT# 58 tezampanel NGX# 58 Gattex 58 trastuzumab DM1 58 ISTODAX 58 CORT # 58 immunomodulatory therapy 58 REOLYSIN ® 58 velaglucerase alfa 58 Evoltra R 58 Imprime PGG 58 ILUVIEN ® 58 LibiGel ® 58 PRESEPT 58 TKB# 58 AIM HIGH 58 ORMD 58 Phase III registrational 58 ORENCIA ® 58 ROCKET AF 58 inhibitor RG# 58 leading oral taxane 58 ACTEMRA TM 58 squalamine 58 safety tolerability 58 tasocitinib 58 BR.# 58 pralatrexate injection 58 generation NNRTI 58 BiTE R 58 AMR# 58 MDV# 58 sorafenib Nexavar 58 Targretin capsules 58 alfimeprase 58 Zelrix 58 posaconazole 58 VA# [002] 58 ABSORB clinical 58 DXL# 58 tesetaxel 58 GSK# [002] 58 trabedersen 58 FOLFOX6 chemotherapy regimen 58 INTERCEPT platelets 58 Zensana TM 58 investigational oral 58 Denufosol 58 RLY# 58 Proellex TM 58 initiate Phase 2a 58 vandetanib 58 Evoltra 58 null responder HCV 58 antibody MAb 58 CYCLOSET 58 TroVax 58 OLpur TM H2H 58 omacetaxine 58 bosutinib 58 heavily pretreated 58 Phase III HEAT 58 tiapamil 58 ATL/TV# 58 CIP TRAMADOL ER 58 PEG IFN 58 angiogenesis inhibitor 58 reslizumab 58 intravenous dosing 58 RSD# iv 58 zalutumumab 58 anticancer agent 58 evaluating mipomersen 58 SILENOR TM 58 intranasal formulation 58 cangrelor 58 oxymorphone ER 58 Triapine 58 PF # [002] 58 hematological cancers 58 OMP #M# 58 BiovaxID 58 multi kinase inhibitor 58 OncoGel 58 ridaforolimus 58 DB# [003] 58 EDEMA3 trial 58 hypoxia activated prodrug 58 tramiprosate 58 galiximab 58 liposomal formulation 58 bortezomib Velcade 58 TREANDA 58 ARRY 58 MYDICAR 58 BioNumerik 58 dacetuzumab SGN 58 afatinib 58 Civacir 58 GW# [003] 58 ISENTRESS 58 ALD# 58 Iluvien ® 58 JP-#/fipamezole 58 COU AA 58 BRAF inhibitor 58 low dose cytarabine 58 Phase III metastatic melanoma 58 midstage study 58 Neo Urinary Conduit 58 AEZS 58 Alpharadin 58 dasatinib Sprycel ® 58 Onrigin 58 Octreolin 58 sorafenib Nexavar ® 58 CAMMS#

Back to home page